drugset / Trial / NCT00509379
Non-randomized Safety Study With Bortezomib/Rituximab in Relapsed/Refractory Indolent Lymphoma
Phase 2
Completed
48 enrolled
Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie
Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte · collabFondazione Italiana Linfomi - ETS · collabUniversity of Turin, Italy · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The promising activity of Bortezomib as single agent in low grade lymphoma patients in small studies has led to a number of larger multicenter trials with Bortezomib in combination with Rituximab in mantle-cell lymphoma, follicular lymphoma and marginal zone lymphoma.
Timeline
- Start
- 2006-09
- Primary completion
- 2007-11
- Completion
- 2011-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bortezomib | Small molecule | 1.6 mg/m2 | Intravenous |
| Subject | Rituximab | Monoclonal antibody | 375 mg/m2 | Intravenous |